TD Cowen analyst Brendan Smith raised the firm’s price target on Ginkgo Bioworks (DNA) to $16 from $10 and keeps a Buy rating on the shares.

Ginkgo Bioworks (DNA) announced a research collaboration with Universal Cells, an Astellas (ALPMY) company, to optimize next-generation induced ...

Ginkgo Biloba's lineage dates back more than 290 million years to the Permian period, even predating the era of the dinosaurs. Traditional medicine practitioners have brought a number of health ...

Ginkgo biloba, one of the oldest tree species native to East Asia, is often termed a “living fossil”. It is known to have weathered aeons of environmental upheaval and even the nuclear ...

Research indicates that the components within MemoForce, such as Ginkgo Biloba and Bacopa Monnieri, have demonstrated their potential to support cognitive function, boost memory capacity ...